[This review was originally posted at the Nieman Journalism Lab Diflucan For Sale, on May 4, 2012.]

Parliament’s damning News Corp. report: It was a second straight week of big news in News Corp.’s phone hacking case, as a committee of the British Parliament issued its report on the scandal (PDF), in which the major statement was that Rupert Murdoch is “not a fit person” to run an international media empire like News Corp. The report also targeted three News Corp. executives in particular — former Dow Jones headLes Hinton, former News of the World editor (and current New York Daily News editor) Colin Myler, and former News International lawyer Tom Crone — for their roles in the scandal’s cover-up, Diflucan steet value. The three may be forced to apologize to Parliament.

The New York Times and Guardian both offered good overviews of the report, with the Times focusing more on Murdoch and the Guardian on Hinton, Myler, and Crone, Diflucan For Sale. Both noted that the strong language about Murdoch was decided along political lines, with liberals voting to put it in and conservatives trying to keep it out. Capital’s Tom McGeveran wrote a helpful explanation of what it means for Parliament to call Murdoch “unfit” (he probably won’t get his broadcast licenses revoked anytime soon), and NPR’s David Folkenflik also had a good breakdown of the situation for American audiences. One of the committee’s members, Buy Diflucan without prescription, Tom Watson, offered more of his own thoughts on the scandal, and the Times’ David Carr translated the report for those of us who don’t read Parliament-ese.

News Corp. Diflucan For Sale, responded by issuing a defiant public statement, which contrasted a bit with Murdoch’s more contrite internal memo. Other businesspeople and media barons came to Murdoch’s defense, and the British broadcaster BSkyB, of which News Corp. owns a share and recently tried to take over, about Diflucan, distanced itself from News Corp. in an effort to hang onto its broadcast license.

There’s other trouble for News Corp., too: A Washington ethics group has called on the FCC to revoke News Corp.’s Fox broadcast licenses in the U.S., and in Britain, opponents of News Corp.’s BSkyB takeover bid said they had been blocked from meeting with the government department in charge of approving the deal. There is some good news for News Corp., Diflucan alternatives, though — the second half of the British government’s inquiry into the company may never happen.

As for the toll on News Corp., the Times has a solid big-picture view of the scandal’s impact so far, and Reuters’ Jack Shafer looked at the escape routes Murdoch could take, Diflucan For Sale. The Columbia Journalism Review’s Ryan Chittum said this report, and Murdoch’s testimony last week, have gone a long way in exposing News Corp.’s culture of corruption: “The glib denials that have served him so well for so many years aren’t working anymore—not with all we now know.” And the Guardian’s Henry Porter went further, writing the (probably premature) political obit for Murdoch.

 

Mixed signals on newspaper circulation: The Audit Bureau of Circulations issued its twice-annual report on newspaper circulation this week — here are its top 25 papers and a database of every daily newspaper in the U.S. Overall, newspapers saw a slight gain in daily circulation, Diflucan price, including a 63 percent gain in paid digital circulation, which, as paidContent noted, includes tablet or smartphone apps, paywalled website subscriptions, and other e-editions. Buy Diflucan from mexico, The common narrative drawn from those numbers was that, as Ad Age put it, “digital paywall strategies have helped newspapers counter years of grinding declines in paid-print circulation.” Poynter’s Steve Myers looked at some of the top circulation gainers and saw that many of them had instituted digital pay plans, while very few of the losers had.

Media analyst Alan Mutter pushed back Diflucan For Sale,  against that conclusion, noting that when you isolate print circulation, almost everyone’s numbers were down, whether they had a paywalled site or not. The circulation increase, it turns out, came from including those digital numbers (and, as Ad Age pointed, possibly counting subscribers twice), not from successfully protecting the print product.

A few newspapers that were highlighted: DCist noted that The Washington Post’s circulation drop was the largest of any of the nation’s top papers, while Poynter’s Andrew Beaujon said the decline wasn’t as bad as it appeared. J-prof Dan Kennedy looked at the numbers for the Boston papers, and the Lab’s Justin Ellis wrote about the story behind the Minneapolis Star Tribune’s increase in circulation and revenue, and its paywall.

 

Is tech in another bubble?: New York Times tech writer Nick Bilton became the latest to raise the specter of a bubble in the tech industry this week, where can i find Diflucan online, reporting on the practice of startups being encouraged by their investors not to make money so as to make it easier to come up with ungrounded, outrageously high valuations. Said one Stanford professor he talked to: “This is 1999 all over again, but this time, it’s gotten worse…We’re back to companies throwing around funny money. The economic values don’t add up.”

This started another round of debate over whether we are, Diflucan mg, in fact, in the midst of another tech bubble. BetaBeat put together a helpful scorecard of who chimed in on which side, and you can read a smart, extended discussion among many of those people at Branch, Diflucan For Sale. Tech blogger Dave Winer said the true sign of whether we’re in a bubble is whether the startups being formed are good businesses that make sense and will grow (and answered that, yes, that means we’re in a bubble).

Investor and blogger Chris Dixon argued that the true measures of a bubble are actually quite nuanced, and we’re getting mixed signals in many of them, though he said no good investors engage in the “flipping” practices Bilton described, japan, craiglist, ebay, overseas, paypal, because it’s not a good business strategy anyway. Tech blogger MG Siegler agreed, calling stories like Bilton’s “a bunch of vague fear mongering.” GigaOM’s Mathew Ingram said it appears as though the inflated valuations are coming in at the small, early seed-money end, which presents less of a danger to the public. Entrepreneur Michael Mace made a similar point, Cheap Diflucan, arguing that until those inflated dollar amounts hit public stock offerings, this market won’t look much like the late ’90s bubble.

Twitter tries to further personalize your news: Twitter moved a bit deeper into personalized news this week with the revamp of its Discover feature Diflucan For Sale, , which will put a heavier weight in its algorithm on links shared by the people you follow to help you find links you’ll be interested in. (All Things D has a good description of the change.) The Next Web’s Drew Olanoff said the new format gives Twitter’s information some social context, which is a big part of what was missing before.

Mathew Ingram of GigaOM argued that while the update is an improvement, Twitter still needs to build better filters to personalize and make sense of its information, before others do it instead. YouTube’s Hunter Walk pointed out, buy Diflucan no prescription, though, that it’s extremely hard for a single product to guess at what you like, what your friends like, and what the world likes, especially in a linear format like Twitter’s.

Elsewhere in Twitter news, After Diflucan, the Lab’s Adrienne LaFrance wrote about journalistic behavior by regular Twitter users, and news execs argued over whether social media is helping or hurting journalism.

Reading roundup: A few other interesting stories, and a couple of thoughtful viewpoints to direct you to this week, Diflucan For Sale.

— The FCC voted last Friday to require local TV stations to put their information about political advertising online, starting in the largest markets. Free Press applauded the decision as a victory for transparency, though ProPublica noted they won’t be searchable. Before the vote, Poynter’s Steve Myers pointed out how resistant TV stations have been to reporting on this issue, Diflucan no rx.

— As The Next Web first reported this week, the Washington Post planned to buy the social news site Digg. That report was followed up with reports that the Post was hiring most of Digg’s staff Diflucan For Sale, , but not buying the site or its technology, leaving the remaining people there to scramble to figure out the site’s future.

— In an engaging book excerpt in New York magazine, Jeff Himmelman revealed that Watergate hero Bob Woodward’s longtime editor at the Washington Post, Ben Bradlee, had misgivings about some of the details about some of the sources Woodward and Carl Bernstein contacted, Diflucan price, coupon, including Deep Throat. Woodward disputed the book’s claims, Himmelman defended them, and the Post’s Erik Wemple said he was skeptical of the reports of Bradlee’s doubts, too. Reuters’ Jack Shafer pointed out that this conflict is only about the All the President’s Men story, not the Post’s actual reporting.

— Two great posts of tips for journalists: Poynter’s Craig Silverman with a list of resources on how to verify information on social media, buy Diflucan online no prescription, and the Guardian’s advice for journalists of the future.

— Finally, Danish scholar Rasmus Kleis Nielsen wrote an insightful piece for Reuters based on some ongoing research he’s doing on what’s hindering news startups in Europe. He calls it “irrational imitation” of the dominant online model of decades past.

Similar posts: Buy Armour No Prescription. Purchase Lipitor. Flagyl Mg. Bactrim photos. Effects of Retin A. Where can i buy Synthroid online.
Trackbacks from: Diflucan For Sale. Diflucan For Sale. Diflucan For Sale. Diflucan coupon. Diflucan no prescription. Comprar en línea Diflucan, comprar Diflucan baratos.

[This review was originally posted at the Nieman Journalism Lab Synthroid No Rx, on April 22, 2011.]

Is Flipboard a competitor or collaborator?: Flipboard has quickly become one of the hottest news apps for the iPad, and it continued its streak last week when it announced it had raised $50 million in funding. Flipboard's Mike McCue told All Things Digital's Kara Swisher he'd be using the money to hire more staff and expand onto other devices, including the iPhone and Android platform. But he also talked to TechCrunch about using the money to fend off a rumored competitor in development at Google. (The Houston Chronicle's Dwight Silverman told Google not to bother, because Zite already does the trick for him.)

All this prompted a fantastic analysis of Flipboard from French media consultant Frederic Filloux, buying Synthroid online over the counter, who explained why Flipboard's distinctive user-directed blend of news media sites, RSS feeds, and social media is so wonderful for users but so threatening to publishers. Filloux argued that every media company should be afraid of Flipboard because they've built a superior news-consumption product for users, Where to buy Synthroid, and they're doing it on the backs of publishers. But none of those publishers can complain about Flipboard, because any of them could have (and should have) invented it themselves.

GigaOM's Mathew Ingram advised media companies to be willing to work with Flipboard for a similar "if you can't beat 'em, join 'em" reason: Its app has their apps beat in terms of customizability and usability, so they're better off trying to make money off of it than their own internal options, Synthroid No Rx. ReadWriteWeb's Dan Rowinski wrote about the possibility that Flipboard could be a better alternative partner for publishers than Apple, and Marshall Kirkpatrick wondered why publishers are up in arms about Flipboard in the first place.

—

Traditional media's personalized news move: One of the reasons that media companies might be less than willing to work with Flipboard is that some of them are building their own personalized news aggregation apps, two of which launched this week: The Washington Post Co.'s Trove and Betaworks' News.me, developed with the New York Times, buy Synthroid without prescription. INFOdocket's Gary Price has the best breakdown of what Trove does: It uses your Facebook account and in-app reading habits to give you personalized "channels" of news, determined by an algorithm and editors' picks — a bit of the "Pandora for news" idea, as the Post's Don Graham called it. (It's free, Synthroid steet value, so it's got that going for it, which is nice.)

All Things Digital's Peter Kafka suspected that Trove will be most useful on mobile media, as its web interface won't be much different from many people's current personalized home pages, and David Zax of Fast Company emphasized the social aspect of the service.

News.me is different from Trove in a number of ways Synthroid No Rx, : It costs 99 cents a week, and it's based not on your reading history, but on what other people on Twitter are reading. (Not just what they're tweeting, but what they're reading — Betaworks' John Borthwick called it reading "over other people's shoulders.") It also pays publishers based on the number of people who read their content through the app, Synthroid duration. That's part of the reason it's gotten the blessing of some media organizations that aren't typically aggregator friendly, like the Associated Press.

Since News.me is based so heavily on Twitter, it raises the obvious question of whether you'd be better off just getting your news for free from Twitter itself. Synthroid mg, That's what Business Insider's Ellis Hamburger wondered, and Gizmodo's Adrian Covert answered a definitive 'no,' though Martin Bryant of The Next Web said it could be helpful in stripping out the chatter of Twitter and adding an algorithmic aspect. GigaOM's Mathew Ingram looked at both services and concluded that they signal a willingness by some traditional media outlets to adjust their longtime broadcasting role to the modern model of the "Daily Me."

—

A good sign for the Times' pay plan: The overall news from the New York Times Co.'s quarterly earnings report this week wasn't good — net income is down 57% from a year ago — but there was one silver lining for online paid-content advocates: More than 100,000 people have begun paying for the Times' website since it began charging for access last month, Synthroid No Rx. (That number doesn't include those who got free subscriptions via Lincoln, but it does include those who are paying though cheaper introductory trials.)

As Advertising Age's Nat Ives pointed out, there's a lot that number doesn't tell us about traffic and revenue (particularly, where can i cheapest Synthroid online, as paidContent's Staci Kramer noted, how many people are paying full price for their subscriptions), but several folks, including Glynnis MacNicol of Business Insider, Low dose Synthroid, were surprised at how well the Times' pay plan is doing. (Its goal for the first year was 300,000 subscribers.) She said the figure compares favorably with the Financial Times, which got its 200,000th subscriber this year, nine years into its paywall, Synthroid canada, mexico, india.

Those numbers are particularly critical for the Times given the difficulty its company has had over the past several years — as Katie Feola of Adweek wrote, many analysts believe the pay plan is crucial for the Times' financial viability. "But this means the paper's future rests on an untested model that many experts believe can't work in the oversaturated news market," she wrote. "And the Times has to pray the ad market won’t decline faster than analysts predict."

A few other paid-content tidbits: Nine of Slovakia's largest news organizations put up a paywall together this week, and the pope is apparently pro-paywall, Synthroid use, too. At the Guardian, Cory Doctorow mused about how companies can (and can't) get people to pay for the content online in an age of piracy.

—

Google's hammer falls on eHow: When Google applied its algorithm adjustment last month Synthroid No Rx, to crack down on content farms, Demand Media's eHow actually came out better off (though others didn't fare so well, like the New York Times Co.'s About.com, as we found out this week). Google made a second round of updates last week, and eHow got nailed this time, losing 66% of their Googlejuice, Synthroid from mexico, according to Sistrix.

Search Engine Land's Matt McGee speculated that Google might have actually been surprised when eHow benefited the first time, and may have made this tweak in part as an effort to "correct" that. Demand Media, Synthroid treatment, meanwhile, called Sistrix's eHow numbers"significantly overstated," though the company's stock hit a new low on Monday. Mathew Ingram said investors have reason to worry, as Demand's success seems to be at the mercy of Google's every algorithm tweak.

—

A Pulitzer first: The Pulitzer Prizes were announced this week, and while the awards were spread pretty broadly among several news organizations, there were a couple of themes to note, Synthroid No Rx. As Felix Salmon and others pointed out, buy generic Synthroid, an abnormally large share of the awards went to business journalism, a trend the Columbia Journalism Review's Dean Starkman opined on in a bit more detail.

The biggest prize from a future-of-news perspective may have gone to ProPublica, whose series on some of the machinations that worsened the financial crisis was the first Pulitzer winner to never appear in print. Purchase Synthroid online, The Lab's Justin Ellis noted that other winners are including significant multimedia components, perhaps signaling a shift in the emphasis of one of journalism's most elite institutions. If you were wondering where WikiLeaks was in all this, well, the New York Times didn't submit its WikiLeaks-based coverage.

—

Reading roundup Synthroid No Rx, : No huge stories this week, but a few little things that are worth noting:

— Your weekly AOL/Huffington Post update: Jonathan Tasini came out swinging again regarding his lawsuit on behalf of unpaid HuffPo bloggers, Business Insider's Glynnis MacNicol responded in kind, Eric Snider told the story of getting axed from AOL's now-defunct Cinematical blog, and HuffPo unveiled features allowing readers to follow topics and writers.

— Missouri j-school students are chafing against requirements that they buy an iPad (they previously had to buy iPod Touches, canada, mexico, india, and they called that plan a bust). Meanwhile, Ben LaMothe of 10,000 Words had three ideas of social media skills that j-schools should teach.

— A weird little fake-URL spoof turned into an interesting discussion about the possibility of libel through fake URLs, in thoughtful posts by both the Lab's Andrew Phelps and TechCrunch's Paul Carr.

— Two interesting data points on news innovation: A group led by Daniel Bachhuber put together some fascinating figures about and perspectives from Knight News Challenge grant recipients. And journalism researchers Seth Lewis and Tanja Aitamurto wrote at the Lab about news organizations using open API as a sort of external R&D department.

Similar posts: Order Armour. Glucophage Dosage. Lipitor Mg. Effects of Lipitor. Where can i order Retin A without prescription. Flagyl photos.
Trackbacks from: Synthroid No Rx. Synthroid No Rx. Synthroid No Rx. Synthroid pictures. Synthroid pics. Synthroid overnight.

[This review was originally posted at the Nieman Journalism Lab Tramadol Dosage, on June 18, 2010.]

The FTC's last round of input: The U.S. Federal Trade Commission wrapped up its series of forums on journalism and public policy Tuesday, and this forum got quite a bit more attention than the others — partly because it's the last one, and partly because the FTC released its draft of possible policy proposals a few weeks ago, which gave people something concrete to pick apart.

Before the forum, Tramadol use, The New York Times' Jeremy Peters and TBD's Steve Buttry both gave good summaries of what various people are saying about the issue, and Save the News' Fiona Morgan gave a helpful, detailed description of what went on at the forum itself. As for the FTC's final report due out this fall, Poynter's Rick Edmonds and Bloomberg Businessweek's Olga Kharif both wrote that we're unlikely to see any proposals for significant government intervention in the news business. Edmonds offers a handful of reasons that the idea has fallen out of favor: Newspapers' financial fortunes have improved lately, we've seen an explosion of strongly backed digital journalism experiments, Tramadol wiki, the government might not be able to do it well, and news organizations themselves aren't sure what they want from Uncle Sam. Both Edmonds and Kharif also noted that Congress won't be willing to be seen as bailing out another for-profit industry.

A few more voices — media economics professor Robert Picard, TBD's Mandy Jenkins and conservative Denver Post columnist David Harsanyi — joined the anti-subsidy chorus this week, and the Times' Eric Pfanner provided some evidence to back them up, pointing out that countries with the largest direct subsidies for newspapers also have the lowest newspaper readership, Tramadol Dosage. (He also noted the U.S. media's extreme reliance on advertising compared with the rest of the world.)

Other folks offered a few ideas of what policy proposals they'd like to see the FTC endorse. Edmonds wants to see nonprofits allowed to accept advertising, Buy Tramadol from mexico, j-prof C.W. Anderson says public policy has a role in "fostering an entrepreneurial, innovative, reinvented journalistic sphere," Salon's Dan Gillmor stumps for open broadband subsidies, and Save the News' Josh Stearns lists five ideas he wants endorsed. Tramadol Dosage, The themes that run across several of those people's proposals are clear: Net neutrality, expanded broadband, open government data, and encouragement for innovation, rather than protection for traditional media businesses.

—

Google News goes human: One low-key but potentially significant development from late last week: As the Lab's Megan Garber reported, after Tramadol, Google News began an experiment called Editors' Picks, in which editors from partner news organizations like the BBC and the Washington Post curate lists of news articles to go along with Google's algorithm-run selections. Garber notes what a shift this is from Google's historical approach to news aggregation and ties it to the quest for serendipity: "This is one way of replicating the offline experience of serendipity-via-bundling within the sometimes scattered experience of online news consumption," she says.

GigaOM's Mathew Ingram saw in the project a similar sign of a shift toward human-powered news aggregation at Google, No prescription Tramadol online, though he noted that Google has tried numerous news-related experiments that never caught on. That's exactly what a Google spokesperson told paidContent's Staci Kramer, and both sites mentioned Google's ill-fated commenting experiment as an example.

Still, Mashable's Vadim Lavrusik loved this idea, making a case for the value of human editors in making sure that people are reading what they need to know online as well as what they want to know, Tramadol Dosage. In other Google News news, its creator, Krishna Bharat, gave a long interview in which he discussed its role in journalism and his idea of what the future of journalism might look like, buy Tramadol without prescription.

—

Murdoch picks up some paid-content pieces: Rupert Murdoch's News Corp. continued its long, steady march toward a paid-news future with a few small but potentially important moves this week: It bought the Skiff mobile software platform from the newspaper chain Hearst — not the Skiff e-reader itself, though it seems they're working on that — invested in Journalism Online, Steve Brill's news paid-content venture, and bid to take full control of British Sky Broadcasting, Europe's largest for-pay broadcaster.

Hollywood Reporter's Andrew Wallenstein called the first two moves huge news for the digital news business, arguing that Murdoch is setting the standard for the way everyone else does business online. "This is about laying the groundwork for the very process by which people pay for that news; namely, the device they consume it on and the virtual storefront that handles the payment, is Tramadol safe," he wrote. Tramadol Dosage, And with BSkyB's digital music and broadband services, it looks like Murdoch's hoping to add another major asset in his plans to find new ways to get people to pay for not only news, but digital entertainment media as well.

—

A theory of the political press defined: If you've been following NYU professor Jay Rosen on Twitter or reading his blog for any length of time, you've probably absorbed a general sense of his guiding philosophy about the American political press. But this week he posted the definitive explanation of that philosophy, which is most simply that political journalists' prevailing ideology is one of false equivalency between two sides of political extremists, Tramadol no prescription, while they (and their favorite politicians) stand at the sane, savvy, skeptical center. It's obviously just one critic's opinion, but it's a remarkably helpful frame to help interpret what the Washington press corps values and why it does what it does.

There's some fascinating discussion about Rosen's ideas in the lengthy comments of his post, and he got a few thoughtful responses elsewhere, as well, Tramadol no rx. The Atlantic's Conor Friedersdorf agreed with the main thrust of Rosen's argument, though he challenged the assertion that political journalists are "big believers in the law of unintended consequences" who don't pay much attention to the direct consequences of public policy. The Economist likewise endorses the post but counters that Rosen's concepts of "he said, she said journalism" and "the sphere of deviance" are at odds, Tramadol Dosage. Over at Slate, Tom Scocca affirms a point of Rosen's about journalists' disregard for street protests, and Australian journalist Jonathan Holmes adapted the concept to the Australian media. Doses Tramadol work, Also, the Atlantic's Marc Ambinder — as a political editor, part of the tribe Rosen was dissecting — asked the professor what he would have the political press think instead. Rosen has promised an answer.

—

Future-of-news thoughts and innovation: Before we get to the reading roundup, a note on a couple of interesting items that the Lab has been highlighting this week. Tramadol Dosage, First, our sister publication, Nieman Reports, has published its quarterly issue, which is always chock-full of thought-provoking essays on journalism in transition. This summer's issue is titled "What's Next for News?" so it's right along the lines of the stuff we write about here at the Lab, where can i order Tramadol without prescription. The Lab has been pointing out several of the issue's 36 pieces — including thoughts on the Internet's effects on our thinking, the editor-as-gatekeeper role, and the semantic web — but there's plenty more out there, so go look around.

Second, Buy cheap Tramadol no rx, the Knight News Challenge announced the 12 winners of its $2.74 million worth of grants for innovative journalism projects. The Lab's Josh Benton has a rundown of the winners and a few observations about the crop as a whole, and we've got profiles of a few of the initiatives, too. There's Stroome, the wiki-style collaborative video-editing site; Public Radio Exchange, a crowdfunding project for public radio journalism; and Order in the Court 2.0, an effort to open up courtrooms through new media, Tramadol Dosage. They should have several more profiles up over the next few days (probably even before this post is published) if you're in the mood to be encouraged by innovation in news.

—

Reading roundup: Two ongoing discussions, one news economics development, Tramadol gel, ointment, cream, pill, spray, continuous-release, extended-release, and one thoughtful piece on context:

— Two news economics experts, Alan Mutter and Frederic Filloux, weighed in this week with their assessments of iPad news apps so far. Mutter looks at the winners and losers, and Filloux talks about what makes iPad news apps work. Online buying Tramadol, — We've been hearing for a couple of weeks about what the Internet is (or isn't) doing to our brains, and that conversation continued with a defense of the web by The New York Times' Nick Bilton a caution to doomsayers by psychology professor Steven Pinker.

— Consulting firm PricewaterhouseCoopers estimated this week that Internet ad revenue will surpass newspaper ad revenue by 2014. Both will still remain behind TV ad revenue, they said.)

— Finally, former journalist John Zhu wrote a wonderful explanation of the state of, well, explanation in the news. (Complete with helpful visual aids!) If you're interested at all in how journalists can make complex stories more understandable to people, this is the perfect place to start putting together where we've been and where we could be going.

Similar posts: Diflucan Cost. Diflucan For Sale. Armour Price. Cipro alternatives. Armour blogs. Diflucan duration.
Trackbacks from: Tramadol Dosage. Tramadol Dosage. Tramadol Dosage. Tramadol class. Tramadol pics. Tramadol trusted pharmacy reviews.